Trends in primary endocrine therapy utilization among patients with early-stage ER+/HER2− breast cancer who do not undergo surgery: A National Cancer Database analysis.
44 Background: Primary endocrine therapy (pET) is a mainstay of cancer treatment for patients with estrogen receptor-positive (ER+) breast cancer who are unfit for surgery. As the multidisciplinary breast oncology teams continue to personalize cancer therapies for patients, we have noticed pET being expanded to...